Abstract:A near‐infrared‐II (NIR‐II) (1000–1700 nm) excitation phototheranostic (BTZ/Fe2+@BTF/ALD) is developed by integrating a dopamine‐modified NIR‐II absorbing small molecule, the anticancer drug bortezomib, and Fe2+ ions, into bone‐targeting ligand alendronate modified amphiphilic PEGylated phospholipid for NIR‐II fluorescence imaging and NIR‐II photoacoustic imaging‐guided NIR‐II photothermal, chemotherapy, and chemodynamic therapy of breast cancer bone metastases. To improve bone metastases treatment efficacy, current strategies are focused on the integration of chemotherapy with phototheranostic. However, the success of phototheranostic approaches is hampered by the limited tissue penetration depth of near‐infrared‐I (NIR‐I) light (700–900 nm). In this study, a NIR‐II (1000–1700 nm) excitation phototheranostic (BTZ/Fe2+@BTF/ALD) is presented for NIR‐II fluorescence imaging and NIR‐II photoacoustic imaging‐guided NIR‐II photothermal therapy (PTT), chemotherapy, and chemodynamic therapy (CDT) of breast cancer bone metastases. This phototheranostic is developed by integrating a dopamine‐modified NIR‐II absorbing donor–acceptor–donor small molecule (BBT‐FT‐DA), the boronate anticancer drug bortezomib (BTZ), and Fe2+ ions, as CDT catalysts, into an amphiphilic PEGylated phospholipid modified with the bone‐targeting ligand alendronate. In acidic and hydrogen peroxide (H2O2) over expression tumor microenvironment, the boronate–catechol linkage is cleaved and BTZ and Fe2+ ions are released to initiate the Fenton reaction, that is, chemotherapy and CDT, respectively, are initialized. It is confirmed using the murine 4T1 bone metastasis model that BTZ/Fe2+@BTF/ALD significantly suppresses the progression of tumor cells in the bone tissue via a synergistic NIR‐II PTT/chemotherapy/CDT effect. Overall, this work provides fresh insights to guide the development of NIR‐II phototheranostics for breast cancer bone metastases.

NIR‐II AIE Liposomes for Boosting Type‐I Photodynamic and Mild‐Temperature Photothermal Therapy in Breast Cancer Treatment

Radiolabeled AIE Probes As Dual-modality Imaging Agents for PET/NIR-II Fluorescence-Guided Photothermal Therapy

Near‐Infrared II AIE Luminogens with Mitochondria‐Targeting Characteristics for Combinational Phototherapies of Breast Tumors Through Synergistic Cell Apoptosis and Pyroptosis

High‐Performance NIR‐II Fluorescent Type I/II Photosensitizer Enabling Augmented Mild Photothermal Therapy of Tumors by Disrupting Heat Shock Proteins

NIR-II Excitation Phototheranostic Nanomedicine for Fluorescence/Photoacoustic Tumor Imaging and Targeted Photothermal-Photonic Thermodynamic Therapy.

NIR‐II Excitation Phototheranostic Platform for Synergistic Photothermal Therapy/Chemotherapy/Chemodynamic Therapy of Breast Cancer Bone Metastases

NIR-II emissive multifunctional AIEgen with single laser-activated synergistic photodynamic/photothermal therapy of cancers and pathogens

Near-infrared-II Light Excitation Thermosensitive Liposomes for Photoacoustic Imaging-Guided Enhanced Photothermal-Chemo Synergistic Tumor Therapy

An All‐rounder for NIR‐II Phototheranostics: Well‐Tailored 1064 nm Excitable Molecule for Photothermal Combating Orthotopic Breast Cancer

Dual-modal Imaging-Guided Agent Based on NIR-II Aggregation-Induced Emission Luminogens with Balanced Phototheranostic Performance

Sterically Twisted Mitochondria‐Targeting Photosensitizers for Augmented Near‐Infrared II Fluorescence‐Guided Photodynamic Immunotherapy

Achieving Efficient NIR‐II Type‐I Photosensitizers for Photodynamic/Photothermal Therapy upon Regulating Chalcogen Elements

Nir‐Ii Emissive Superoxide Radical Photogenerator for Photothermal/photodynamic Therapy Against Hypoxic Tumor

NIR-II Light Excited Heptamethine Cyanine/Prodrug/Albumin Nanoparticles for Photothermal/Photodynamic/Chemo Combination Therapy

Efficient NIR-II Type-I AIE Photosensitizer for Mitochondria-Targeted Photodynamic Therapy through Synergistic Apoptosis-Ferroptosis

Genetically Engineered Cell Membrane Modified Conjugated Polymer Nanoparticles for NIR‐II Photothermal Therapy

Aggregation‐Induced Emission Near‐Infrared (NIR)‐II‐Conjugated Polymers Coupled With Nonconjugated Segments for NIR‐II Fluorescence Imaging–Guided NIR‐II Photothermal Therapy

Near-infrared photosensitizers adaptive to tumor hypoxic microenvironment for synergistic photothermal-photodynamic and immunotherapy

NIR-II fluorescence imaging guided tumor-specific NIR-II photothermal therapy enhanced by starvation mediated thermal sensitization strategy

Semiconducting Polymer Nanoparticles for NIR-II Fluorescence Imaging-Guided Photothermal/thermodynamic Combination Therapy.

Self-shrinking supramolecular nanoparticles syndicate energy suppression and NIR-II mild photothermal amplification of mitochondrial oxidative stress for breast cancer therapy